Vigil Neuroscience Elects Directors at Annual Meeting

Vigil Neuroscience Inc ( (VIGL) ) just unveiled an announcement.

On May 22, 2025, Vigil Neuroscience, Inc. held its Annual Meeting of Stockholders, where a quorum was present. The stockholders voted to elect two Class I directors to the board and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Both proposals were approved by the stockholders.

The most recent analyst rating on (VIGL) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Vigil Neuroscience Inc stock, see the VIGL Stock Forecast page.

Spark’s Take on VIGL Stock

According to Spark, TipRanks’ AI Analyst, VIGL is a Underperform.

Vigil Neuroscience Inc’s stock score is primarily affected by its weak financial performance, characterized by no revenue generation and negative cash flows. The technical analysis shows some short-term positive momentum, but valuation concerns and the overbought condition suggest caution. The lack of earnings call and corporate events data means these factors did not influence the score.

To see Spark’s full report on VIGL stock, click here.

More about Vigil Neuroscience Inc

Vigil Neuroscience, Inc. operates in the biotechnology industry, focusing on developing therapies for neurodegenerative diseases. The company’s primary products or services are centered around innovative treatments aimed at addressing unmet medical needs in neurological health.

Average Trading Volume: 716,420

Technical Sentiment Signal: Buy

Current Market Cap: $367.8M

Learn more about VIGL stock on TipRanks’ Stock Analysis page.